LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Edwards Lifesciences Corp

Suletud

SektorTervishoid

78.27 0.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

78.13

Max

78.36

Põhinäitajad

By Trading Economics

Sissetulek

-27M

332M

Müük

120M

1.5B

P/E

Sektori keskmine

32.703

34.427

Aktsiakasum

0.64

Kasumimarginaal

21.636

Töötajad

15,800

EBITDA

-34M

400M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+13.72% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. okt 2025

Turustatistika

By TradingEconomics

Turukapital

978M

46B

Eelmine avamishind

78.17

Eelmine sulgemishind

78.27

Uudiste sentiment

By Acuity

23%

77%

45 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Edwards Lifesciences Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

25. okt 2024, 09:10 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25. okt 2024, 08:35 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3. sept 2024, 20:38 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3. sept 2024, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3. sept 2024, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

Võrdlus sarnastega

Hinnamuutus

Edwards Lifesciences Corp Prognoos

Hinnasiht

By TipRanks

13.72% tõus

12 kuu keskmine prognoos

Keskmine 89 USD  13.72%

Kõrge 101 USD

Madal 80 USD

Põhineb 26 Wall Streeti analüütiku instrumendi Edwards Lifesciences Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

26 ratings

16

Osta

10

Hoia

0

Müü

Tehniline skoor

By Trading Central

74.52 / 75.54Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

45 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.